Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00046137 · ClinicalTrials.gov registry record · Phase 3

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

A Phase 3 study of Osteoporosis, Postmenopausal, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
13
Study locations

NCT00046137: Completed Phase 3 study of Osteoporosis, Postmenopausal, sponsored by Eli Lilly and Company.

NCT00046137 is a Phase 3 study of Osteoporosis, Postmenopausal that has completed, run by Eli Lilly and Company. The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00046137, a Phase 3 study of Osteoporosis, Postmenopausal, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
13
Study locations

Study Summary

The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporosis more than teriparatide alone.

Conditions Studied

Osteoporosis, Postmenopausal

Interventions

  • DRUG placebo
  • DRUG raloxifene
  • DRUG teriparatide

Study Locations (13)

California

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Anaheim
  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Oakland

Maryland

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Baltimore
  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Hagerstown

Florida

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Altamonte Springs

Illinois

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Chicago

Iowa

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Cedar Rapids

New Jersey

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Voorhees Township

Ohio

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Cleveland

Oklahoma

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Oklahoma City

Trial Details

FieldValue
Phase Phase 3
Eli Lilly and Company

1,341 total trials

What the finished NCT00046137 record still lists

NCT00046137 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00046137 lists 13 locations in 11 states (California, Maryland, Florida).

Frequently Asked Questions

What is clinical trial NCT00046137 about?

NCT00046137 is a clinical study titled "Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis". The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporos...

What is the current status of trial NCT00046137?

This trial is currently completed. It is a Phase 3 study.

What conditions does trial NCT00046137 study?

This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.

What interventions are being tested in trial NCT00046137?

The interventions under investigation include: placebo (DRUG), raloxifene (DRUG), teriparatide (DRUG).

Who is sponsoring clinical trial NCT00046137?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00046137 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoporosis, Postmenopausal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00046137, the US trial registry maintained by the National Library of Medicine. NCT00046137 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.